South Korea · Health Care · KRW (Millions) · Annual
Key financials
KRW|Millions
ROE
-20.04%
2025 (actual)
ROA
-18.55%
2025 (actual)
Gross Margin
12.66%
2025 (actual)
Net Margin
-189.05%
2025 (actual)
Total Assets
₩66,903.41M
2025 (actual)
Net Income
-₩13,340.02M
2025 (actual)
Valuation
₩231,507.13M
2026 (forecast)
Stock Price
₩9,990
Historical & projected performance
KRW|Millions
Reported figures and Equlion model projections for the next 5 years.
ROE
+91.1 pt
Company
ROA
-27.1 pt
Company
Gross Margin
-7.3 pt
Company
Sector average
Net Margin
-209 pt
Company
Total Assets
+33.1%
Company
Sector average (own scale)
Net Income
-195.2%
Company
Sector average (own scale)
Valuation
+188.2%
Company
Sector average
Stock Price
+188.2%
Company
Sector average
Amounts in KRW (millions); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Stock price and valuation carry no data date: they are the Equlion model's estimate for 2026. Projections are model estimates, not investment advice.
Want the full financial forecast report for Vaxcell-Bio Therapeutics Co., Ltd.? It covers the balance sheet, income statement, cash flow and Equlion model projections.